Bio-Path Holdings, Inc. (OTCQB: BPTH): Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (OTCQB: BPTH) for Q1 2025. Bio-Path Holdings, Inc. (OTCQB: BPTH) is a clinical-stage ...

Roth Capital revised its price target for Bio-Path Holdings Inc. (OTC:BPTH) to $2 from $9, while keeping a Buy rating on the ...

The trial will initially involve healthy obese people receiving single and multiple escalating doses of the therapy.

PASADENA, CA, USA I June 02, 2025 I Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in a Phase 1/2a ...

Major players including AbbVie, GSK, Sanofi, and Eli Lilly recently bolstered their R&D pipelines with a wave of acquisitions ...

NEW YORK – Arrowhead Pharmaceuticals on Monday said it has treated the first patients with ARO-ALK7, an RNAi therapeutic that the company is developing for obesity, within a first-in-human Phase I/IIa ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has initiated the human trial of ARO-ALK7, a novel RNA interference (RNAi) ...

Learn about May 2025’s top biotech deals, featuring major collaborations in RNA interference technology, small molecules, and ...

Bicara Therapeutics presented data from an ongoing, 28-patient trial of its drug showing median overall survival of over 21 ...

Rona Therapeutics Co. Ltd. has reported preclinical data for its RNA interference (RNAi) therapy RN-026 targeting lipoprotein(a) (Lp[a]).

Arrowhead Pharmaceuticals, Inc.'s deal with Sarepta expands its pipeline, but limited plozasiran market and competition ...

In a 2014 Nature paper, Ralston described this awkward process — trogocytosis, or “cell nibbling.” It was a revelation at the ...